You are here

Article Text

Article menu
Download PDFPDF
Letter
Complications of management in primary acquired melanosis with atypia
  1. Devron H Char
  1. The Tumori Foundation, San Francisco, CA, USA and Department of Ophthalmology, Stanford University, Stanford, CA, USA
  1. Dr Devron H Char, The Tumori Foundation, 45 Castro Street, Suite 309, San Francisco, CA 94114, USA; devron{at}tumori.org

https://doi.org/10.1136/bjo.2007.116491

Statistics from Altmetric.com

    Request Permissions

    If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.

    The management of conjunctival primary acquired melanosis (PAM) with atypia is in flux. Lesions are treated with biopsy, excision, adjunctive cryotherapy, or topical mitomycin.1 Acceptable, usually minimal, complications have been reported with these adjunctive therapies.2 Adverse events associated with topical mitomycin are uncommon and punctual stenosis is observed, especially in cold windy climates in approximately 20% of cases. Limbal stem cell deficiency has been described after the use of this agent on a dose-related basis, but is uncommon.2 3

    We report a case of recurrent PAM with atypia treated with three courses of mitomycin and two courses of cryotherapy, with subsequent stem cell deficiency and vision …

    View Full Text

    Footnotes

    • Competing interests: None declared.

    • Supported in part by a grant from the Tumori Foundation. The author has no financial interest in the subject matter.